|
| |
BioJournal - Datamonitor
http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor.html
 |
Key issues in head and neck cancer including disease overview and
epidemiology, current treatment patterns and controversies, unmet needs and
key stakeholder opinions. The clinical pipeline and profiles of the
late-phase products are also included. |
|
|
The systemic antifungals market accounts for $3.1bn of the total $41bn
anti-infectives market. A wave of new products coinciding with patent expiry
of two widely used compounds will shake up the market for systemic
infections, further polarizing between winners and losers. Key changes are
forcing a rethink of management strategies and clinical trial design. |
|
|
The current Huntington’s disease market is comprised of off-label
prescriptions of psychotropic drugs. In the near term, two pipeline drugs
are set to enter the market, demonstrating the viability of this disease as
a primary marketing indication. In the longer term, with a strong genetic
link and reliable diagnostic test, prophylactic treatment with a disease
modifying drug could prove lucrative. |
|
|
With Pharma struggling to maintain its pipelines and portfolios with
products developed in-house, companies are increasingly turning to
licensing. However, the search for late-stage developmental products is
becoming tougher and more expensive, and companies are now looking towards
licensing earlier-stage compounds. |
|
|
The high prevalence of nicotine dependence, strong uptake of Pfizer’s
Chantix (varenicline), and the launch of new innovative therapies will cause
the nicotine dependence prescription drug market to grow to $4.6 billion
across the seven major markets by 2016. Innovative therapies are set to
offer patients a convenient dosing regimen and thereby carrying the
potential for improved compliance. |
|
|
Fuelled by an increasing disease awareness, the growing use of new,
expensive drugs as well as combination therapy, the HBV drugs market, sized
at $431m in 2006 across the seven major markets, will nearly triple in size
by 2016. Rapid growth until 2011 will slow down in the following years as a
result of genericization and the beginning impact of routine HBV
vaccination. |
|
|
Datamonitor expects the cardiovascular market to remain stable with
sales only showing negligible growth between 2006 and 2016, below the 3%
growth predicted for the SU sold. Generic products will become increasingly
important as the majority of products will have lost IP protection,
accounting for 30% of cardiovascular sales and 65% of SU sold in 2016. |
|
|
Approaches to cancer treatment continue to incorporate molecular
targeted therapies into standard treatment regimens. With an increasing
number of candidates gaining approval, and with a dynamic developmental
pipeline, further clinical, commercial and strategic challenges are
continuing to emerge. |
|
|
Drug targets are the critical link between drugs and their role in the
treatment of medical disorders. By grouping drug targets into key protein
families, this report provides a comprehensive analysis of the prescription
pharmaceutical market by not just molecule type and therapy area, but also
by target family. |
|
|
Stroke is one of the top three leading causes of death worldwide and an
area of high unmet needs. TPA is limited to a low number of ischemic stroke
patients due to a short therapeutic time window, but it is still the best
therapy available. TPA is responsible for major changes and advances in the
way stroke patients are cared for, which is expected to evolve further. |
|
|
In the 7 major markets, Datamonitor estimates that the incidence of RCC
in 2007 will total 86,800 cases. Around 25% of all RCC patients are
diagnosed with Stage IV disease; the 2-year survival rate for these patients
is around 23%. This low survival rate and the fact that a significant
proportion of Stage IIII patients relapse with Stage IV disease mean there
is significant unmet need in RCC. |
|
|
Datamonitor expects the antithrombotics market to peak at just over $20
billion in 2012, across the seven major markets. The growth will be driven
by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's
Rendix - which are expected to launch simultaneously, in 2008. |
|
|
The market for infertility drugs is a complex and dynamic arena shaped
by numerous factors such as changing social attitudes, national legislation,
and prescriber preferences. Brand strength and diverse portfolios have
allowed Organon, Merck Serono and Ferring to secure a firm foothold in the
market, worth over $1 billion in 2006, and represent tough competition. |
|
|
The allergic rhinitis market will continue to decline over the next few
years, after which it will resume limited growth due to the introduction of
new compounds and combination products. These will drive the expansion of
sales in existing classes as they exhibit safety and convenience advantages.
Meanwhile, immunotherapy is expected to move from its niche position into
mainstream therapy. |
|
|
The upper GI market, defined as gastroesophageal reflux disease (GERD),
peptic ulcer disease (PUD) and dyspepsia indications, achieved sales of just
over $19 billion in 2006, with minimal growth since 2005. All major PPI
brands will lose patent protection in the next 10 years, resulting in a
major increase in generics and a declining market value. |
|
|
Despite several developments in efforts to tackle the spread of HIV, the
total number of people living with HIV has continued to increase across the
6MM. However, significant advances in HIV disease understanding, treatment
and management mean that the outlook for patients has considerably improved. |
|
|
Datamonitor's Orthopedics: Global Industry Guide is an essential
resource for top-level data and analysis covering the orthopedics industry.
It includes detailed data on market size and segmentation, textual analysis
of the key trends and competitive landscape, and profiles of the leading
companies. This incisive report provides expert analysis on a global,
regional and country basis. |
|
|
Datamonitor's Biotechnology: Global Industry Guide is an essential
resource for top-level data and analysis covering the biotechnology
industry. It includes detailed data on market size and segmentation, textual
analysis of the key trends and competitive landscape, and profiles of the
leading companies. This incisive report provides expert analysis on a
global, regional and country basis |
|
|
Datamonitor's Generics: Global Industry Guide is an essential resource
for top-level data and analysis covering the generics industry. It includes
detailed data on market size and segmentation, textual analysis of the key
trends and competitive landscape, and profiles of the leading companies.
This incisive report provides expert analysis on a global, regional and
country basis. |
|
|
Significant barriers to entry into the biosimilars market exist. High
up-front investment and the need for specific expertise favor big players.
Understanding of the marketplace is critical for success acceptance by key
stakeholders is crucial for market uptake of biosimilars and achieving
preferential reimbursement status through constant review of the pricing
strategy is desirable. |
|
|
In 2007, more than 3 million new cases of solid tumors are forecast to
be diagnosed across the seven major pharmaceutical markets, obviously
representing an enormous market potential. Lower incidence tumor types are
becoming increasingly attractive to drug developers, due to high levels of
unmet need which can result in significant financial rewards. |
|
|
The PD market is set to continue to grow over the next 7 years, reaching
over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations,
reformulations, and indication expansions will drive the majority of this
growth, with key brands expected to be Novartis/Orion's Stalevo,
GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro. |
|
|
NICE is one of the most advanced cost effectiveness assessment bodies
operating in the major pharmaceutical markets. Since it was established it
has had an increasing impact on the availability of new drugs in England and
Wales, but has also generated considerable attention globally |
|
|
The neuropathic pain market is forecast to double from 2006 to reach
over $7 billion by 2016. At this time, the current late-stage neuropathic
pain pipeline is forecast to take only 18% of the total market share,
highlighting an opportunity for better pipeline drugs that demonstrate
improved pain management. The most promising and closest pipeline drug to
market is UCB's Vimpat (lacosamide). |
|
|
With the seven triptan brands continuing to dominate acute migraine
treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the
prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1%
from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total
in 2006, Whilst in the 5EU, France is the largest market for
migraine-specific drug sales. |
|
|
"IntroductionThis report provides a comprehensive strategic analysis of
the mAb market out to 2012 by company. It identifies four 'established' and
four 'emerging' players within the mAb sector which are forecast to play the
most commercially significant role within this market. |
|
|
The long-standing unmet need of the osteoporosis market has been for
improved adherence to treatment. Two pipeline products, Amgen's Denosumab
and Novartis' Aclasta (zoledronate), have answered this demand with
intermittent dosing schedules and consequently are expected to generate
blockbuster revenues. This will rejuvenate the market which is otherwise
stalling under multiple patent expiries. |
|
|
Europe serves as a model for other countries looking to define their own
regulatory approval criteria. The US is on the brink of passing legislation
to establish a statutory pathway for biosimilars approval but the opposing
interests of biosimilar and innovative companies may result in further
delays. Development of biosimilars presents many challenges and potential
pitfalls. |
|
|
The Hospital antibacterials market accounted for $9.9bn of the total $41bn
anti-infectives market. Increasingly resistant and problematic pathogens
make this an attractive target for premium priced products outside of the
largely genericized Community market. However, high concentrations of patent
expiries and similarly targeted product launches imply a highly competitive
commercial landscape. |
|
|
Social media are shifting the way that the global economy operates.
Internet journals and communities have enabled consumers to communicate
their experiences with companies' products and services to other consumers.
A consequence of consumer-generated marketing is that relationship
management throughout the lifecycle of a product is taking the place of mass
marketing in consumer-driven industries. |
|
|
The diabetes epidemic has contributed in the growth of the antidiabetics
market the past few years. Since the prevalence of diabetes continues to
increase, the market will further expand. While early therapy is dominated
by generically available agents, and the later stages by insulin, the number
of unmet needs in the diabetes treatment, warrants that novel agents will
have a place in the market. |
|
|
With fewer truly novel products entering the market, combined with
increasing developmental time and spend, and declining ROI, successful
launches have never been more important for pharmaceutical companies.
Therefore, to ensure a successful launch, manufacturers must employ a
multitude of timely strategies to ensure their product enter the market as
soon and as smoothly as possible. |
|
|
Datamonitor expects few new products to emerge from a week pipeline for
both acute and chronic heart failure. Sales in the seven major markets will
be modest with all the new drugs being add-on therapies to current standard
regimes. Significant unmet patients needs will remain in both acute and
chronic heart failure. |
|
|
Waves of technological advancements have powered significant evolution
in R&D from serendipitous drug discovery, through to rational drug design.
However, as the low-hanging fruit has been picked, and recent technological
advances have failed to yield high numbers of new therapies, the search is
on to identify R&D strategies to improve R&D productivity |
|
|
Female sexual dysfunction (FSD) affects an estimate 84 million women
across the seven major pharmaceutical markets and represents a significant
opportunity for investment. Despite its high prevalence, FSD is poorly
understood and defined. Currently there is just one product approved for the
treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany,
France and the UK. |
|
|
The pediatric and adolescent vaccines market encompasses many different
classes. DTP and MMR combinations continue to form the mainstay of childhood
immunization; however, their growth potential is limited. The key
opportunities lie in novel, innovative additions to established schedules,
particularly pneumococcal (Prevnar), conjugated meningococcal (Menactra) and
HPV (Gardasil) vaccines. |
|
|
Datamonitor has identified the key trends and events that drive patient
empowerment and impact the pharmaceutical industry. These range from the
increased access to information via internet and the rising pressures of
cost containment through to how patient empowerment is affecting access to
drugs as well as changing pharmaceutical marketing strategies and their
public image. |
|
|
Datamonitor expects the antihypertensives market to reach almost $40
billion, across the seven major markets, by 2016. The growth will be driven
by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and
their combinations. However, the expiries of some key patents, particularly
Pfizer's Norvasc and Merck's Cozaar, will restrain market growth. |
|
|
The restrictive, highly competitive antidyslipidemic market is going to
become even further genericized, which will add to the challenges that drug
makers are facing. Despite over 300m people being eligible for
antidyslipidemic treatment, there is still a lot of under-diagnosis and
under-treatment, but it will be a major issue capturing all the eligible
population. |
|
|
Detailed analysis of the Asthma and COPD market. 10 year sales forecast
for all major drugs brands in these indications, taking into account new
treatment trends, clinical trial data, patent expirations and key new
product launches in the 7 major markets. |
|
|
Detailed analysis of the antiretroviral therapy market. 10 year sales
forecast for marketed drugs and key pipeline compounds, factoring in
clinical trial results, new product launches and patent expiries.
Scope of this report
* In-depth analysis of the current HIV market across the major US and EU
markets
* Thorough assessment of underlying commercial and clinical factors shaping
the antiretroviral market
* Detailed sales forecasts for the three major antiretroviral classes,
molecules and brands in each of the six major markets
* Case study analysis of the entry inhibitor class focusing on the
competitive environment and critical success factors |
|
|
Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and
peptic ulcer disease (PUD) represent a group of common gastrointestinal (GI)
conditions, which can be referred to collectively as upper GI disorders.
Gastric acid suppression remains the cornerstone of therapy in upper GI
disorders, with particular focus on reducing symptoms and eradicating H.
pylori, if present. |
|
|
Sales of the Top 20 cancer therapy brands in each of the seven major
markets totaled $24.5 billion in 2006 and are forecast to grow at a CAGR of
6.6% to $45.9 billion by 2016. Four newly marketed drugs are expected to
become part of the Top 20 cancer therapy brands during the forecast period
and are set to increase the 2016 sales of the existing Top 20 cancer therapy
brands to $52.7 billion. |
|
|
Failure to take medication as prescribed significantly increases the
risk that patients will experience complications resulting in injury or
death, and propagate higher healthcare costs overall. The medical
establishment's approach to adherence is changing as it becomes clear that
the responsibility of achieving adherence is not solely the patient's, but
rather is shared among stakeholders. |
|
|
Incidence of primary brain cancer across the seven major markets in 2007
is estimated to be 47,000. Over half of these cases will be glioblastoma
multiforme, for which survival prospects are dismal. The median survival for
this group of patients is 1.2 years and only 27% of patients are alive after
two years. The level of unmet need is therefore high in this disease. |
|
|
Novel pipeline drugs, lifecycle management of the current branded
antidepressants, and development of atypical antipsychotics for depression
are set to grow the depression market through to 2010 when it will peak at
$14.6 billion. Thereafter, however, generic incursion of the atypical
antipsychotics and the remaining branded antidepressants will see the
depression market value drop to 2016. |
|
|
Ambien has remained the clear leader in the insomnia market for over a
decade, with 2006 sales of over $2.3 billion across the seven major markets.
The success of Ambien is attributable to a favorable side-effect profile and
half-life. However, due to recent patent expiries in the US and Japan,
Ambien's leadership status is finally under threat and the market is
undergoing some dramatic changes. |
|
|
The dynamic MS market continues to grow unabated; seven major market
revenues increased 14.7% from 2005 to $4.6 billion in 2006. Growth is driven
by the highly successful beta-interferon brands, Teva's Copaxone (glatiramer
acetate), and the recent relaunch of Tysabri; the first launch of a new MS
treatment for six years. |
|
|
The osteoporosis market is due a major upheaval when market leader
Fosamax (alendronate) loses its US patent. The resultant heightened
competition will force market players to implement radical lifecycle
management strategies to safeguard their franchise revenue. New market
entrants provide further complexity to the competitive landscape but will
also drive market growth over the next ten years. |
|
|
The report provides a comprehensive financial and strategic analysis of
the mAb market, forecasting its commercial evolution out to 2012 and
assessing trends by product, company, therapy area, technology and target
type. It also provides an insight into the direction of mAb technology
evolution and an analysis of pipeline dynamics. |
|
|
The telehealth market will continue to grow as the population,
particularly the elderly and chronically ill, and technology adoption
increase. |
|
|
The telehealth market will continue to grow as the population,
particularly the elderly and chronically ill, and technology adoption
increase. |
|
|
Irritable bowel syndrome (IBS) is a common disease affecting 1020% of
the total adult population, particularly women, in which recurrent abdominal
pain or discomfort is associated with defecation or changes in bowel habit.
The majority of sufferers have never consulted a physician about their
symptoms and remain undiagnosed. |
|
|
Supportive care can be defined as those products used to prevent and/or
treat the adverse side effects that arise as a result of the tumor itself or
administration of anticancer therapies, in particular cytotoxic
chemotherapy. While the antihormonal therapies and novel molecular targeted
therapies do not exist without some toxicity, these are not as severe as
those associated with chemotherapy. |
|
|
The close association with hepatitis means that hepatocellular carcinoma
(HCC) is common in developing countries where hepatitis B and C infections
are endemic. However, the increasing prevalence of hepatitis in the West
means that incidence of HCC in the US and Europe is expected to increase
significantly over the coming years. |
|
|
The Canadian pharmaceutical market is the 8th largest globally and as
such represents an important market for generics manufacturers. Although
historically dominated by domestic generics companies, mergers and
acquisitions over the last five years have increased the dominance of
foreign players. |
|
|
Patients in a clinical population receive drug and non-drug therapy for
female sexual dysfunction, yet a third remain refractory to treatment,
highlighting a need for a formally approved product for FSD. There is a low
level of satisfaction with the classification guidelines, further limiting
diagnosis, already hampered by embarrassment, lack of physician awareness
and an unclear referral system. |
|
|
Mainly affecting women, fibromyalgia syndrome affects six million people
in the US alone. This relatively common yet poorly understood syndrome is
characterized by widespread muscle pain and fatigue and remains
substantially underserved by the medical profession and the pharmaceutical
industry. Currently, there are no drugs licensed to treat fibromyalgia in
the US, Japan or Europe. |
|
|
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving
over the last decade. The success of the next wave of novel RA therapies
depends on their ability to address the key issue of cost effectiveness, as
the patient population for anti-TNF's is reaching a maximum and competition
moves to anti-TNF failure patients. |
|
|
The launch of serotonin antagonists which are largely aimed at treating
sleep maintenance is set to make a substantial impact on the insomnia
market, which will increase in value across the seven major markets from
$6.1 billion in 2006 to $7.7 billion in 2016. |
|
|
With declining returns from drug development pipelines, preservation of
branded revenues is key for manufacturers. Inevitably though, once the core
product patent of a pharmaceutical drug expires, generic companies will
launch their own, cheaper versions of the drug, encouraging product
switching and eroding the revenues of branded pharmaceuticals. |
|
|
Novel oral anticoagulants and antiplatelet agents will have a profound
impact on the antithrombotics market. Datamonitor expects Bayer's
rivaroxaban and Sankyo/Eli Lilly's prasugrel to achieve blockbuster status.
Parenteral anticoagulants are not expected to be large revenue generators,
due to low clinical unmet need in this market segment and strong competition
from current gold standard agents. |
|
|
At present, despite the availability of numerous agents for the
treatment of dyslipidemia, there is significant scope for expanding the
market by improving diagnosis and treatment of dyslipidemia patients.
However, for new agents, gaining a secure foothold on the market will be
challenging, but their chances can be improved through targeting niche
patient populations and conducting outcome trials. |
|
|
The influenza vaccine market, sized at approximately $2.2 billion in
2006, yields many challenges. Demand is highly variable, and only large
players are able to cope with the need for annual updates and the costly
manufacturing process. However, driven by the increasing pandemic threat,
the market is growing fast and is predicted to more than double in size by
2016. |
|
|
Unmet needs across the hematological malignancies remain high, with most
traditional therapies conferring low levels of specificity and high
toxicity. Pipeline candidates classified as molecular targeted therapies,
cytotoxic therapies and immunotherapeutic agents, may offer attractive
therapeutic additions and Datamonitor's insight into their clinical and
commercial potential is provided. |
|
|
The launch of five novel orally administered disease-modifiers is set to
revolutionize the multiple sclerosis (MS) market, which will more than
double in value across the seven major markets from 2006 to reach $10.7
billion in 2016. |
|
|
The roll-out of Part D in January 2006 represented a significant leap
forward, since it provided coverage for outpatient drugs for Medicare
patients for the first time. A high number of both patients and insurance
providers are now involved in the program, as a result of strong patient
enrollment. |
|
|
An estimated 34 million people are diagnosed with asthma in the major
markets. The disease can be broken down into various phenotypes,
differentiated by severity, trigger, or predominant inflammatory type. These
phenotypes may have important consequences for future approaches to treat
asthma in a more targeted fashion, doing away with the one-size-fits-all
approach. |
|
|
Datamonitor believes that companies developing pipeline drugs for the
depression market should concentrate resources on targeting third-line
depression patients, a market with significant sales volume and few viable
treatment options. GSK's gepirone ER is likely to be the first pipeline drug
to enter the market and exploit this opportunity, with forecast sales of
$615m in 2016. |
|
|
In the US and Europe, an estimated 510% of patients are expected to
develop an infection during their hospital stay. The four main types of
infections that occur within the hospital setting are urinary tract
infections, hospital acquired pneumonia, surgical site infections and
blood-stream infections, accounting for approximately 35%, 15%, 14% and 10%
respectively. |
|
|
Technology has been used to either inform or expedite the prescribing
process in most modern healthcare systems for over two decades. Recently,
market forces - including greater regulatory intervention, increased
investment from stakeholders and decreased resistance from end-users - have
begun to converge to set the stage for widespread adoption of truly
integrated ePrescribing solutions. |
|
|
Atopic dermatitis is a skin disorder characterized by intense itch, dry
skin and redness. Often considered a benign disease, it actually impacts
very negatively on quality of life, sometimes more than psoriasis and
diabetes. Through opinion leader interviews, Datamonitor has identified a
high level of unmet need in atopic dermatitis treatment and believe that a
number of market opportunities exist |
|
|
SCLC accounts for one-fifth of all lung tumor types. More than 80,000
new cases are expected to be diagnosed in 2007 in the seven major markets,
although it is set to decrease due to changing smoking habits. Mesothelioma
is rarer, although incidence is expected to increase in the coming years in
Europe and Japan given the heavy use of asbestos in the 1970s and long
latency period of the disease. |
|
|
Globally, esophageal cancer is the ninth most common tumor type and
seventh leading cause of cancer-related death, however, its incidence
fluctuates widely depending on geographical area. While relatively uncommon
in Western countries, 50% of patients still present with locally advanced
unresectable or distant metastatic disease, where treatment is complicated
and chances of a cure are reduced. |
|
|
Datamonitor has identified the key trends and events that impacted the
pharmaceutical market on a macro-environmental and corporate strategy level
in 2006. These range from the continuation of long term trends such as the
focus on cost containment to more recent impacts such as the effects of
Medicare Part D and the increasing power of the Democratic part in the US. |
|
|
An understanding of the present and future market trends surrounding
eHealth is vital in order for the pharmaceutical industry to develop
effective multi-channel marketing strategies. It is advisable for
stakeholders to invest in targeted initiatives that meet the specific
information needs and support the decision making processes of the large
numbers of physician and consumer groups online. |
|
|
The HIV market generated $7.4 billion of sales in 2005 and experienced a
CAGR of 13.3% from 2001-2005, making it one of the fastest growing
infectious diseases sub sectors. Despite the antiretroviral market's
relative immaturity, many older flagship products such as Combivir are
expected to lose patent protection before 2015. |
|
|
There is no cure for psoriasis, which profoundly affects sufferers
quality of life, physical and social functioning. There is a particular
unmet need for effective long-term therapies for psoriasis. Prevalence is
the highest of the autoimmune diseases at 16 million in 2006, but this is
deceptive in terms of market size, as the treated and severe patient
populations are comparatively small. |
|
|
The 2004 withdrawal of Vioxx from the global market had a negative
effect on the COX-2 class, with a 44% fall in Celebrex sales for
osteoarthritis in 2005. However, as patients sought an alternative to the
COX-2s, there was positive growth in traditional NSAIDs, non-narcotic
analgesics, narcotic analgesics, corticosteroids and HA viscosupplements,
leading to a 1.1% increase in total market value. |
|
|
Atherosclerosis generally begins in childhood and manifests clinically
in mid-to-late adulthood. While the mortality from atherosclerotic
conditions has declined significantly, in developed countries cardiovascular
disease accounts for nearly 50% of all deaths, and within the next 15-20
years, is projected to surpass infectious diseases to become the leading
cause of death worldwide. |
|
|
The disease-modifying drugs are considered by physicians to represent a
significant advance for the management of MS. However, none is fully
effective and there are problems with regards to side effects, dosing
regimens and cost. Tysabri, a novel once-monthly drug is expected to be an
improvement in terms of efficacy; however, there remains a concern over side
effects and long-term safety. |
|
|
The erectile dysfunction market grew 3.5% from 2005 to be worth $1.95
billion in 2005 and is almost entirely composed of sales from three brands:
Viagra (sildenafil), Cialis (tadalafil) and Levitra (vardenafil). Despite
the dominance of these products, several opportunities exist for a
successful market entry. |
|
|
Melanoma comprises just 5% of all skin cancers but it is the most
deadly. In 2006, more than 100,000 cases of the disease are expected to be
diagnosed in the seven major pharmaceutical markets. High unmet needs still
persist for this tumor type and despite three decades of extensive R&D,
five-year survival of advanced patients remains below 20%. |
|
|
RSV mostly causes upper respiratory tract infections (URTI), resulting
in the common cold. However, in certain risk groups, RSV can cause more
severe lower respiratory tract infections (LRTI) leading to bronchiolitis.
These risk groups include elderly people, patients with underlying pulmonary
or cardiac disease, premature infants, children under four years old and
immunocompromised patients. |
|
|
CRM is a business strategy by which a company seeks to maximize the
value of its products by managing the customer relationship, with specific
aims to boost customer retention and increase market share, while reducing
the costs of sales, marketing and customer fulfillment. CRM is made
necessary because of advances in Web-enabled technologies, which have
changed the dynamics of sales and marketing. |
|
|
Based on an analysis of 46 companies and 1,000+ products, Datamonitor
forecasts that pharmaceutical industry ethical sales will increase at a
modest 4.9% CAGR 200511. However, behind this industry average figure there
are strategic segments of the market that offer double-digit growth rates
through barriers against generic competition and the opportunity for
aggressive indication broadening. |
|
|
With increasing regulatory clarity and the expiries of key patents
covering innovator biologics, the development of biosimilars for a range of
recombinant protein classes is becoming increasingly attractive. Although
many companies are targeting the market, 12 companies dominate. These
include established generics companies, leading biosimilars developers, plus
emerging biosimilar developers. |
|
|
Datamonitor predicts a somewhat enthusiastic uptake of two agents
currently in development by 2015. However, reimbursement is critical to the
uptake of new medication, due to the high cost of therapy. If the
reimbursable status is not achieved, the expansion of the market will not
match the rate of growth of the obese population and the great potential of
the obesity market will remain untapped. |
|
|
The global antibacterial market, valued at $25.5 billion in 2005, is
highly mature. Modest growth (CAGR 2001-2005: 5.1%) is fuelled by ageing,
immunosuppression and emerging resistances, especially in the hospital and
former niche markets (e.g. MRSA). The community market, however, is facing a
value loss following the patent expiries of several blockbusters (e.g.
Pfizer's Zithromax) in 2005. |
|
|
Unmet needs across the cancer market remain high, with most therapies
conferring low levels of specificity and high toxicity. Therapeutic cancer
vaccines offer an attractive therapeutic addition, delivering treatment of
high specificity, low toxicity and prolonged activity. However, despite
years of R&D, a reproducible survival benefit has proved elusive, leaving
the market wide open. |
|
|
A lack of prescriber adherence to both marketing licenses and
pharmacoeconomic guidelines represents both a challenge and opportunity for
pharmaceutical companies marketing current Alzheimer's disease drugs.
Indication expansion between disease severities may not be a viable
commercial option; conversely, stricter guidelines by bodies such as the
UK's NICE will not necessarily threaten the market. |
|
|
The Chinese pharmaceutical market, although only positioned ninth
globally, has experienced pronounced and rapid expansion in recent years,
driven by the growth of both Chinese and Western manufacturers.
Increasingly, there is a shift towards a research-based industry, focused on
generating new, innovative therapies, supported by improving intellectual
property regulations. |
|
|
The ageing of the population will result in an increased incidence of
coronary artery disease, heart failure and stroke. In addition to these
epidemiological forces, the antithrombotics market will be sustained by the
forthcoming launch of innovative novel agents whose sales revenue is
expected to dampen the commercial impact of generic incursion in blockbuster
proceeds. |
|
|
After the launch of Trexima in 2007, triptan genericization coupled with
a weak late-stage pipeline will result in a major shift in market dynamics,
and will result in the migraine market value decreasing to $3.2 billion in
2015. The market remains receptive to superior prophylactics however, with
innovation being essential for the progression of the acute market,
post-triptan era. |
|
|
The oncology market has shown remarkable growth in recent years, driven
by the advent of targeted therapy and the high level of unmet needs in the
disease, and it is poised for further expansion. While this will provide
companies with opportunities, a key hurdle for novel cancer drugs will be
the increasing pharmacoeconomic vigilance that prevails within cash-strapped
healthcare systems. |
|
|
Cases of endometrial cancer are set to rise in developed countries due
to an increase in risk factors such as obesity. In contrast, while incidence
of cervical cancer is set to decrease in developed countries following the
implementation of anti-HPV immunization with Merck & Co's Gardasil and
GlaxoSmithKline's Cervarix, it will remain a major cause of cancer-related
death in the developing world. |
|
|
The drive for increased cost savings by healthcare providers is increasing
the focus on boosting the biosimilar market. With a regulatory approval
pathway in place in Europe and substantial guidelines to support biosimilar
development, the European biosimilars market is significantly more advanced
than the US, where plans for a biosimilar regulatory approval pathway have
stalled. |
|
|
Datamonitor's Drug Delivery: Global Industry Guide is an essential
resource for top-level data and analysis covering the drug delivery
industry. It includes detailed data on market size and segmentation, textual
analysis of the key trends and competitive landscape, and profiles of the
leading companies. This incisive report provides expert analysis on a
global, regional and country basis. |
|
|
Datamonitor's Biotechnology: Global Industry Guide is an essential
resource for top-level data and analysis covering the biotechnology
industry. It includes detailed data on market size and segmentation, textual
analysis of the key trends and competitive landscape, and profiles of the
leading companies. This incisive report provides expert analysis on a
global, regional and country basis. |
|
|
Today, consumers are taking a more proactive approach to managing their
health and the prevention of diet-related diseases, such as obesity,
diabetes, cardiovascular and bone and joint diseases. Many of these diseases
are at epidemic levels, and this combined with increasing patient power
makes the prevention of these lifestyle diseases attractive markets for both
the food and pharmaceutical industries to exploit. |
|
|
Datamonitor's Generics: Global Industry Guide is an essential resource
for top-level data and analysi | |
